A new dawn for osteoporosis drug development The Lancet Diabetes & Endocrinology ++... ++

A new dawn for osteoporosis drug development The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00011-2/fulltext?dgcid=raven_jbs_etoc_email Mar 2026 Volume 14Number 3p187-274, e3-e6 https://www.thelancet.com/journals/landia/issue/vol14no3/PIIS2213-8587(26)X2001-0 Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial Albert Wiegman, MD PhDa a.wiegman@amsterdamumc.nl ∙ Prof Amy L Peterson, MD MSb ∙ Prof Eric Bruckert, MDc ∙ Joep C Defesche, PhDd ∙ Anja Schweizer, PhDe ∙ Prof Jean Bergeron, MDf ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00351-1/abstract?dgcid=raven_jbs_etoc_feature_landia The Lancet Summit: shaping the future of diabetes prevention Nov 30–Dec 2, 2026 | Sitges, Spain https://thelancetsummit.com/diabetes-prevention/index.html